EQS-Ad-hoc: Fresenius SE & Co. KGaA / Key word(s): Forecast/Strategic Company Decision
Fresenius has set the strategic course for simplifying the Group structure. As part of a comprehensive range of initiatives, the management board of Fresenius Management SE has also put in place a new financial framework. For 2023, Fresenius now provides full-year guidance for organic sales growth and operating income (EBIT). For 2023, Fresenius expects Group organic revenue (base 2022: €40,840 million) to grow in a low- to mid-single-digit percentage range. Group constant currency EBIT before special items (base 2022: €3,727 million*) is expected to remain broadly flat or decline up to a high-single-digit percentage rate. The range of the decrease compared to the previous year is mainly due to a challenging business environment at Fresenius Medical Care. Excluding Fresenius Medical Care, the Group constant currency EBIT before special items (base 2022: €2,187 million) is expected to remain broadly flat or decline up to a mid-single-digit percentage rate.
The responsible corporate bodies of Fresenius SE & Co. KGaA have resolved to advance with the deconsolidation of its subsidiary Fresenius Medical Care AG & Co. KGaA ("FMC") by way of a change of the legal form of FMC into a German stock corporation (“Aktiengesellschaft”). It is intended to resolve on the change of the legal form in an Extraordinary General Meeting to be convened by FMC for the beginning of the third quarter of 2023. The conversion is expected to become effective by the end of the 2023 financial year. * Before special items; In 2022, operating income was supported by EUR 277 million (at current currency) of U.S. Provider Relief Funding (PRF). There is no additional governmental support assumed for 2023. To provide a comparable basis for the 2023 earnings outlook, the 2022 basis is adjusted accordingly. For additional information on the performance indicators used please refer to our website at https://www.fresenius.com/alternative-performance-measures. (Financial statements according to IFRS) Fresenius SE & Co. KGaA, represented by Fresenius Management SE, The Management Board Bad Homburg v.d.H., February 21, 2023 ---------------------------------------- Contact: Markus Georgi Senior Vice President Investor Relations & Sustainability T: +49 (0) 6172 608-2485 markus.georgi@fresenius.com ---------------------------------------- End of Note
21-Feb-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | Fresenius SE & Co. KGaA |
Else-Kröner-Straße 1 | |
61352 Bad Homburg v.d.H. | |
Germany | |
Phone: | +49 (0)6172 608-2485 |
Fax: | +49 (0)6172 608-2488 |
E-mail: | ir-fre@fresenius.com |
Internet: | www.fresenius.com |
ISIN: | DE0005785604 |
WKN: | 578560 |
Indices: | DAX |
Listed: | Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Hamburg, Hanover, Stuttgart, Tradegate Exchange; Luxembourg Stock Exchange |
EQS News ID: | 1565211 |
End of Announcement | EQS News Service |
|
1565211 21-Feb-2023 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.